文献速递肝病

格卡瑞韦/哌仑他韦6周短程泛基因型治疗近期HCV感染

Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection.
PubMed 文献 · Hepatology · 2020-04-08

这项开放标签、单臂、多中心国际先导研究纳入近期HCV感染(病程<12个月)的成人,给予格卡瑞韦/哌仑他韦300/120 mg每日一次共6周。30例受试者中意向治疗人群SVR12为90%(27/30),符合方案人群为96%(27/28),无治疗相关严重不良事件,支持在该人群中进一步评估缩短疗程的泛基因型治疗。

要点

  • 近期HCV感染成人接受格卡瑞韦/哌仑他韦6周,意向治疗SVR12达90%。
  • 符合方案人群SVR12为96%,仅1例复发、2例非病毒学失败。
  • 研究未观察到治疗相关严重不良事件。

核心结论

  • 格卡瑞韦/哌仑他韦6周短程泛基因型治疗在急性及近期HCV感染者中高度有效,支持进一步评估缩短疗程方案。

研究设计与样本

  • 开放标签、单臂、多中心国际先导研究,纳入近期HCV感染(病程<12个月)的成人,接受格卡瑞韦/哌仑他韦300/120 mg每日一次共6周,主要终点为治疗后12周持续病毒学应答(SVR12)。

主要发现

  • 30例受试者中位年龄43岁,90%为男男性行为者,77%(23例)HIV阳性,47%(14例)曾注射吸毒,13%(4例)为HCV再感染。
  • HCV基因型以1型为主(83%,25例),4型10%(3例),3型7%(2例)。
  • 基线中位估计感染病程29周(范围13–52周),中位HCV RNA为6.2 log10 IU/mL(范围0.9–7.7)。
  • 意向治疗人群SVR12为90%(27/30),符合方案人群为96%(27/28)。
  • 出现1例复发和2例非病毒学失败(死亡1例、失访1例),未见治疗相关严重不良事件。

临床怎么用

  • 对于急性及近期HCV感染者,6周格卡瑞韦/哌仑他韦泛基因型方案显示出高SVR12,可作为缩短疗程的候选策略,但尚需进一步研究验证。

局限性

  • 本研究为单臂先导研究,样本量小(30例),未设对照,结果需在更大规模研究中证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Among treatment-naive individuals with chronic hepatitis C viral (HCV) infection and without cirrhosis, glecaprevir/pibrentasvir for 8 weeks is recommended. The aim of this analysis was to evaluate the efficacy of glecaprevir/pibrentasvir for 6 weeks in people with acute and recent HCV infection. APPROACH AND RESULTS: In this open-label, single-arm, multicenter, international pilot study, adults with recent HCV (duration of infection < 12 months) received glecaprevir/pibrentasvir 300/120 mg daily for 6 weeks. Primary infection was defined by first positive anti-HCV antibody and/or HCV RNA within 6 months of enrollment and either acute clinical hepatitis within the past 12 months (symptomatic seroconversion illness or alanine aminotransferase > 10 × upper limit of normal) or anti-HCV antibody seroconversion within 18 months. Reinfection was defined as new positive HCV RNA within 6 months of enrollment and evidence of prior spontaneous or treatment-induced clearance. The primary endpoint was sustained virologic response at 12 weeks posttreatment (SVR12). Thirty men (median age 43 years, 90% men who have sex with men) received treatment, of whom 77% (n = 23) were human immunodeficiency virus-positive, 47% (n = 14) had ever injected drugs, and 13% (n = 4) had HCV reinfection. The majority had HCV genotype 1 (83%, n = 25), followed by genotype 4 (10%, n = 3) and genotype 3 (7%, n = 2). At baseline, median estimated duration of infection was 29 weeks (range 13, 52) and median HCV RNA was 6.2 log10 IU/mL (range 0.9, 7.7). SVR12 in the intention-to-treat and per-protocol populations was achieved in 90% (27/30) and 96% (27/28), respectively. There was one case of relapse, and there were two cases of nonvirological failure (death, n = 1; loss to follow-up, n = 1). No treatment-related serious adverse events were seen. CONCLUSIONS: Glecaprevir/pibrentasvir for 6 weeks was highly effective among people with acute and recent HCV infection, supporting further evaluation of shortened-duration pan-genotypic therapy in this setting.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Martinello M, Orkin C, Cooke G, et al. Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection. Hepatology. 2020. PMID: 31652357. doi:10.1002/hep.31003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。